ADMA Biologics, Inc. growth

Reported trailing growth, forward expectations and three-year compound growth rates.

Trailing growth

Year over year

Revenue: +11.0%
EBITDA: +37.8%
EBIT: +36.1%
EPS: -20.7%
Free cash flow: +19.1%
Operating cash flow: +26.8%

Forward estimates

Revenue: +37.2%
EBITDA: —
EPS: +50.7%

Three-year CAGR

Revenue: +49.0%
EBITDA: +521.7%
EBIT: +197.5%
Net income: -25.7%
EPS: -27.1%
Free cash flow: +169.9%

Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.